New hope for Hard-to-Treat Hormone-Positive cancers: Z-Endoxifen trial shows promise
NCT ID NCT01273168
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 32 times
Summary
This early-phase trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. The drug works by blocking estrogen from fueling cancer growth, similar to tamoxifen but without needing the liver to activate it. The main goals were to check safety and find the right dose, while also seeing if it could slow tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.